The Rapid Test Ag 2019-nCoVย demonstrated a sensitivity of 96.33% and specificity of 99.62% from an independent clinical trial performed at the Laboratory of Microbiology of the General University Hospital of Larissa, Greece. This is one of the major Reference Laboratories for SARS-CoV-2 testing in the country.
The trial was conducted during the period of December 2, 2020, until January 29, 2021, and for the evaluation 370 samples were used which had been confirmed with RT-PCR.
โ๏ธ To obtain the full validation report for this clinical trial please contact: exports@prognosis-biotech.com
